BACIGUENT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BACIGUENT (BACIGUENT).
Bacitracin inhibits bacterial cell wall synthesis by dephosphorylating the lipid carrier that transports peptidoglycan precursors across the cell membrane, leading to accumulation of toxic intermediates and cell lysis.
| Metabolism | Bacitracin undergoes minimal systemic absorption via topical application; not significantly metabolized; excreted unchanged in urine if absorbed. |
| Excretion | Primarily renal excretion of unchanged drug via glomerular filtration and tubular secretion; >90% of absorbed dose recovered in urine within 24 hours; biliary/fecal elimination minimal (<2%) |
| Half-life | Terminal elimination half-life approximately 2.5–3.5 hours in adults with normal renal function; prolonged in renal impairment (up to 20–30 hours in anuria) |
| Protein binding | Approximately 20–30% bound to serum proteins, mainly albumin |
| Volume of Distribution | 0.25–0.4 L/kg (total body water); limited tissue distribution, primarily extracellular fluid |
| Bioavailability | Topical: negligible systemic absorption (<0.5%) through intact skin; oral: not absorbed (inactivated in GI tract; not used systemically) |
| Onset of Action | Topical: detectable antimicrobial effect within 1–2 hours after application; systemic absorption negligible via intact skin |
| Duration of Action | Bactericidal activity persists 6–12 hours after topical application; systemic levels (if absorbed) decline rapidly due to short half-life |
Topical: Apply thin layer to affected area 1 to 3 times daily; maximum duration of therapy is 1 week.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical use; systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for topical use. |
| Pediatric use | Apply thin layer to affected area 1 to 3 times daily; safety in infants under 2 months not established. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BACIGUENT (BACIGUENT).
| Breastfeeding | Bacitracin is not systemically absorbed from topical use; therefore, breast milk exposure is negligible. M/P ratio is not applicable. Considered safe during breastfeeding when used topically. For systemic use, avoid due to potential nephrotoxicity. |
| Teratogenic Risk | Bacitracin is not systemically absorbed from topical application, so fetal exposure is negligible. No known teratogenic risk in any trimester; however, systemic use (IM) is contraindicated due to nephrotoxicity, and limited data exist for systemic use in pregnancy. Animal studies show no evidence of harm, but human data are insufficient. |
■ FDA Black Box Warning
Due to nephrotoxicity, bacitracin is NOT recommended for parenteral use; topical use only.
| Serious Effects |
["Hypersensitivity to bacitracin or any component of the formulation"]
| Precautions | ["Hypersensitivity reactions including anaphylaxis","Prolonged use may result in overgrowth of non-susceptible organisms, including fungi","Avoid contact with eyes","Not for use on deep wounds or severe burns"] |
| Food/Dietary | No known food interactions with topical bacitracin. Avoid ingestion. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for topical use. For systemic use (IM), monitor renal function (serum creatinine, BUN, urine output) due to nephrotoxicity risk. Fetal monitoring not indicated for topical application. |
| Fertility Effects | No known effects on fertility. Systemic absorption is minimal with topical use. No data suggest impairment of male or female fertility. |
| Bacitracin is a topical polypeptide antibiotic effective against gram-positive organisms. It is often combined with neomycin and polymyxin B in triple antibiotic ointments. For minor wounds, apply a thin layer 1-3 times daily. Avoid use on large body surface areas or for deep puncture wounds due to risk of systemic absorption and nephrotoxicity. Monitor for allergic contact dermatitis, especially with prolonged use. |
| Patient Advice | Clean the affected area before each application. · Apply a thin layer of ointment 1 to 3 times daily. · Do not use on large areas of the body, deep wounds, or animal bites. · Stop use and consult a doctor if the condition worsens or does not improve within 1 week. · Avoid contact with eyes or mucous membranes. |